Microdosing psychedelics has been practiced widely enough and studied long enough that some patterns are emerging, but “long-term effects” remain remarkably poorly characterized. The best-controlled trials so far typically last only a few weeks, and most of the longer-term data comes from surveys and observational studies where expectation and self-selection cloud the picture. What the research does suggest is a mixed bag: some intriguing signals around mood improvement, small biological changes in the brain, and a handful of safety concerns that deserve attention, alongside a persistent difficulty in separating real drug effects from the placebo response.
What People Take and How Often
Microdosing typically involves taking roughly one-tenth to one-twentieth of a full psychedelic dose on a repeating schedule. The two most common substances are LSD and psilocybin mushrooms, which together account for the vast majority of microdosing reports. A large survey found that about half of LSD reports and half of psilocybin reports made up the field, with a scattering of more obscure compounds like mescaline and various synthetic tryptamines filling out the rest.1PLoS ONE. A systematic study of microdosing psychedelics
Most people microdose several times a week rather than daily. Between roughly 57% and 78% of LSD and psilocybin microdosers reported using their substance two to four times per week.2International Journal of Neuropsychopharmacology. Motives and Side-Effects of Microdosing With Psychedelics Among Users The most widely followed schedule is the Fadiman protocol, which calls for one day on and two days off. In a large international survey, about a quarter of regular microdosers reported following this approach.3PubMed. Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics Nearly half of respondents, though, said they had designed their own schedule, highlighting just how informal and self-directed this practice tends to be.4International Journal of Neuropsychopharmacology. Motives and Side-Effects of Microdosing With Psychedelics Among Users
This matters for understanding long-term effects because “long-term microdosing” is not one standardized thing. People are taking different substances, at varying doses, on schedules they often improvise. That makes generalizing from any single study difficult and means the safety data we have is patchy.
What Happens in the Brain at Low Doses
Even at doses too small to cause a trip, psychedelics appear to leave a biological footprint. One placebo-controlled study in healthy volunteers found that 5-microgram and 20-microgram doses of LSD raised blood levels of brain-derived neurotrophic factor (BDNF), a protein linked to the growth and survival of neurons. The effect was measurable within four to six hours of taking the dose.5PubMed Central. Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers BDNF is often discussed in the context of neuroplasticity, the brain’s ability to rewire connections, and a single-day bump in BDNF does not prove lasting brain changes. But it does suggest that microdoses are not pharmacologically inert.
Brain-imaging work tells a similar story. Low doses of LSD have been shown to reduce broadband oscillatory power over the default mode network during rest, a pattern that resembles what happens with full psychedelic doses, just less dramatically. The same study found reduced amplitudes in specific brain-wave components associated with attention and face processing.6PubMed Central. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults These are acute effects measured on dosing day, but they raise a reasonable question: if microdoses subtly reshape brain activity each time they are taken, could months of intermittent use accumulate into something meaningful? That question has not been answered by any long-duration controlled trial.
Mood, Anxiety, and Depression
Mood improvement is the benefit microdosers report most often, and it is where the tension between anecdote and controlled evidence is sharpest. A large observational study that tracked psilocybin microdosers and non-microdosing controls over one month found that microdosers showed greater reductions in depression, anxiety, and stress scores compared to the control group.7Scientific Reports. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls A separate cross-sectional survey of people with mental health concerns found that current microdosers reported lower anxiety and depression scores than non-microdosers.8Scientific Reports. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
These numbers look encouraging, but both studies relied on self-selected participants who knew they were microdosing. When researchers have tried to isolate the drug effect from expectation, the picture softens considerably. A review of the controlled evidence concluded that both LSD and psilocybin at microdoses showed “no, to very subtle, effects on mood state,” and noted that while low LSD doses were sometimes experienced as pleasant, they could also increase anxiety and produce cycling between depressive and euphoric moods.9PubMed Central. The therapeutic potential of microdosing psychedelics in depression A recent systematic review and meta-analysis of randomized controlled trials reinforced this, finding that microdoses of psilocybin and LSD produced subjective and neurophysiological changes but had minimal sustained impact on mood.10PubMed. Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis
So the pattern is consistent: people who microdose tend to feel better, but when you control for the fact that they know they are taking a psychedelic, most of the improvement can be accounted for by expectation. Whether a small genuine drug effect exists underneath the placebo response is still being sorted out.
The Creativity Question
Enhanced creativity is one of the most popular claims in microdosing culture. The controlled evidence here is genuinely mixed, not just absent. Three placebo-controlled trials of psilocybin microdosing found that active microdosing improved the ratio of original responses in a divergent-thinking task, meaning participants generated fewer ideas but those ideas were rated as more original. This effect survived corrections for whether participants guessed they had received the drug, and it was stronger at higher relative doses.11Neuropharmacology. Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
Against this, a separate placebo-controlled LSD microdosing trial found no acute or lasting effects on any of several creativity measures, despite participants reporting they felt more creative on dose days.12PubMed Central. Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide And a double-blind psilocybin mushroom study similarly found no evidence for enhanced creativity, concluding that expectation likely underpins at least some of the anecdotal benefits.13PubMed Central. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
How to read these contradictions? One possibility is that psilocybin and LSD affect creativity differently. Another is that the standard lab tests for creativity, which tend to involve timed word-association and alternative-uses tasks, may not capture the kind of creative thinking microdosers say improves in their daily lives. Or the positive findings could be fragile statistical signals that will not replicate. For now, anyone microdosing specifically for long-term creativity gains should know the evidence is thin and inconsistent.
Cognition and Focus
Beyond creativity, many microdosers hope for sharper thinking, better focus, or improved memory. Two double-blind placebo-controlled trials of psilocybin microdosing tested exactly this and came up essentially empty. The researchers found that microdosing did not significantly affect behavioral or subjective cognitive measures compared to placebo. Some initial signals appeared in social cognition, mood, and self-reported cognitive flexibility, but none survived statistical corrections for the number of comparisons being tested.14PubMed. Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials
This is a place where the research is actually fairly clear: under controlled conditions, microdosing does not appear to boost general cognitive performance. The one psilocybin mushroom trial that looked for cognitive changes found a few small shifts, but they pointed toward impairment rather than enhancement.15PubMed Central. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study If you are microdosing and feel cognitively sharper, the current weight of evidence suggests that expectation is doing most of the work.
The Placebo Problem
Perhaps the most important study for understanding long-term microdosing outcomes is one that tried to disentangle the drug from the belief. A “self-blinding” citizen-science experiment had participants prepare their own microdoses and placebos, shuffle them so they did not know which was which, and follow a four-week protocol. Both the microdose group and the placebo group improved on every psychological outcome. There were no significant between-group differences on the main measures. Some small acute effects appeared on scales like energy, mood, and creativity, but the researchers concluded these could largely be explained by participants correctly guessing which capsules contained the drug.16PubMed Central. Self-blinding citizen science to explore psychedelic microdosing
A follow-up analysis of this same dataset went further by adjusting for how well participants guessed their condition. After that adjustment, almost all of the apparent drug effects vanished. The one exception was self-perceived energy, which remained marginally significant but with a roughly 40% smaller effect size than the unadjusted result.17Scientific Reports. The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing This is a recurring theme in the field: the more carefully you control for what people expect to happen, the smaller the drug effect becomes.
None of this means microdosing “does nothing.” Placebo effects are real neurobiological events with measurable consequences for mood and well-being. But it does mean that someone microdosing for months and feeling better cannot confidently attribute that improvement to the substance itself rather than to ritual, intention-setting, and belief.
Cardiovascular Concerns
The safety risk that researchers take most seriously with long-term microdosing involves the heart. Classic psychedelics like LSD and psilocybin activate the serotonin 5-HT2B receptor, and chronic activation of that receptor is linked to cardiac fibrosis and valvular heart disease. This is the same mechanism behind heart-valve problems caused by certain appetite suppressants and the Parkinson’s drug pergolide, which were pulled from the market partly for this reason.
A review evaluating this risk concluded that the long-term cardiac effects of psychedelic microdosing remain unknown and recommended that future studies include cardiac monitoring.18PubMed Central. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins A separate analysis estimated that the safety margins between microdoses and known heart-valve-damaging drugs are wider than those for established valvulopathogens, but “not without potential risk.”19PubMed. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
On the reassuring side, a mouse study that administered LSD at microdose-equivalent levels found no changes in heart rate, body weight, or echocardiographic structure from the LSD itself. Serotonin, used as a positive control, did produce cardiac changes, but LSD did not.20PubMed Central. Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice A mouse study is not the final word on human safety, but it provides some early evidence that typical microdoses may not hit the 5-HT2B receptor hard enough or frequently enough to cause the kind of damage seen with drugs that were taken daily at much higher receptor occupancy. The honest answer is that nobody knows what happens to human heart valves after a year or more of intermittent psychedelic use, and no trial has looked.
Psychiatric Side Effects and Who Should Be Cautious
While serious psychiatric emergencies have not been observed in controlled microdosing studies, the pattern of reported side effects includes more mood disruption than the popular narrative acknowledges. A systematic review of LSD and psilocybin microdosing found that seven studies reported mood problems, including not just lowered mood but also feeling overwhelmed, manic states, and amplified emotions.21Neuropharmacology. Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes
The same review noted that serious outcomes like hallucinogen persisting perception disorder (HPPD), psychosis, and suicidal thoughts were not observed in the studies it covered. But there is a major caveat: virtually all of these studies excluded people with a history of psychotic disorders or other mental health conditions that would predict a poor response. The absence of serious adverse events in a screened, relatively healthy study population does not mean those events cannot occur in the broader population of people who microdose on their own.22Neuropharmacology. Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes Anyone with a personal or family history of psychosis, bipolar disorder, or schizophrenia should treat the absence of evidence as exactly that, not as evidence of safety.
Tolerance and Receptor Adaptation
One question for long-term microdosers is whether the brain adapts in ways that diminish the effect or change receptor function over time. Psychedelic tolerance at full doses builds rapidly: a large dose today makes the same dose significantly weaker two days later. At microdose levels the picture is less clear, and the available evidence comes mostly from animal work.
A study giving mice intermittent microdoses of DMT (a short-acting psychedelic) for nearly two months found no change in expression of the gene for the 5-HT2A receptor, the primary target of psychedelics. This suggests that the chronic, low-level stimulation from a microdosing schedule may not trigger the same receptor downregulation that a full dose does.23PubMed Central. Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents However, other research using a different psychedelic agonist showed that even single exposures could reduce the density of 5-HT2A receptors in the frontal cortex, and repeated dosing produced a progressive decrease in a behavioral marker of psychedelic activity.24PubMed Central. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
These are different drugs at different doses in mice, so drawing firm conclusions about human microdosers is premature. But the fact that the two studies point in different directions is itself informative. Whether tolerance develops during microdosing likely depends on the substance, the dose, and the schedule. People who microdose for months sometimes report that the effects seem to diminish, while others say they remain stable. Neither experience is surprising given how little we know about receptor dynamics at these low, intermittent exposures.
Personality Shifts
A small prospective study tracked 24 people before and after a period of microdosing and found that conscientiousness increased and neuroticism decreased over time, with no changes in extraversion, agreeableness, or openness.25Journal of Psychedelic Studies. Exploring the relationship between microdosing, personality and emotional insight: A prospective study This is interesting because higher neuroticism and lower conscientiousness are both associated with worse mental health outcomes in the general population, so a shift in the “healthy” direction would be a meaningful change if it is real and durable.
The study was tiny and uncontrolled, which means the personality shifts could reflect expectation, lifestyle changes that coincided with microdosing, or simply regression to the mean. Full-dose psychedelic studies have found similar personality changes, particularly increases in openness, using more robust designs, so the idea that psychedelics can nudge personality traits is not implausible. But the microdosing-specific evidence on this point is preliminary enough that it should be treated as a hypothesis, not a finding.
Sleep Changes
One of the more concrete long-term effects to emerge from controlled research involves sleep. A study analyzing over 3,200 nights of tracked sleep data found that on the night after an LSD microdose, participants slept an extra 24 minutes compared to placebo. This extra sleep included about 8 additional minutes of REM sleep, and the mechanism appeared to be straightforward: people went to bed roughly 25 minutes earlier on the night following a microdose, with no change in wake time.26Translational Psychiatry. LSD increases sleep duration the night after microdosing
No reduction in sleep was observed on the dosing day itself, which is notable because stimulant-like disruption on the day of use is something some microdosers worry about. The practical implication of an extra 24 minutes of sleep every few days is modest on any single night, but sleep researchers have long argued that even small, consistent improvements in sleep duration can compound into meaningful health benefits over weeks and months. Whether this specific effect holds up across different substances, doses, and populations remains to be seen.
Neuroplasticity and Inflammation
Some of the more speculative interest in long-term microdosing centers on whether repeated low doses of psychedelics could provide lasting neuroprotective or anti-inflammatory benefits. Psilocin, the active metabolite of psilocybin, has been described as both a serotonin agonist and an anti-inflammatory agent, with research suggesting it increases neuroplasticity and reduces overactivity in the default mode network.27PubMed. Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity Early-stage research has explored whether these properties could be relevant to conditions like Alzheimer’s disease, where inflammation and loss of neural plasticity play central roles.28PubMed Central. Psilocybin for the treatment of Alzheimer’s disease
These are mechanistic arguments rather than clinical findings. Nobody has demonstrated in a controlled trial that microdosing prevents neurodegeneration or reduces chronic inflammation in humans. The gap between “this molecule does interesting things to neurons in a dish” and “taking tiny amounts of mushrooms protects your aging brain” is enormous. But the basic biology is plausible enough that several research groups are pursuing it, and it represents one of the more scientifically grounded reasons someone might consider microdosing over extended periods, if the safety data eventually support it.
Where the Evidence Actually Stands
The field’s biggest limitation is also its most underappreciated one: almost no controlled studies have lasted longer than a few weeks. Everything we think we know about what happens after months or years of microdosing comes from surveys of people who chose to microdose, knew they were microdosing, and were motivated to attribute their experiences to the substance. That is exactly the setup in which placebo and expectation effects thrive. The self-blinding study described earlier is the best attempt so far at cracking this problem, and its main finding was that most of the psychological benefits dissolved once expectation was accounted for.29PubMed Central. Self-blinding citizen science to explore psychedelic microdosing
What we can say with reasonable confidence is that microdoses are not pharmacologically inert. They raise BDNF, alter brain-wave patterns, shift sleep timing, and activate serotonin receptors that have known downstream consequences. Whether those biological effects translate into durable benefits for mood, cognition, or brain health with repeated use over months is the central unanswered question. And the cardiac-safety question, quiet as it is in the popular conversation, may be the one that matters most if large numbers of people continue microdosing indefinitely without medical monitoring.